Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and aims</h3><p>Atherosclerosis progression and regression studies are related to its prevention and treatment. Although we have gained extensive knowledge on germline phospholipid transfer protein (PLTP) deficiency, the effect of inducible PLTP deficiency in atherosclerosis remains unexplored.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We generated inducible PLTP (iPLTP)-knockout (KO) mice and measured their plasma lipid levels after feeding normal chow or Western-type diets. Adenovirus associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9) was used to induce hypercholesterolemia in the mice. Collars were placed around the common carotid arteries, and atherosclerosis progression and regression in the carotid arteries and aortic roots were evaluated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>On a normal chow diet, iPLTP-KO mice exhibited decreased cholesterol, phospholipid, apoA-I, and apoB levels compared with control mice. Furthermore, the overall amount of high-density lipoprotein (HDL) particles was reduced in these mice, but this effect was more profound for larger HDL particles. On a Western-type diet, iPLTP-KO mice again exhibited reduced levels of all tested lipids, even though the basal lipid levels were increased. Additionally, these mice displayed significantly reduced atherosclerotic plaque sizes with increased plaque stability. Importantly, inducible PLTP deficiency significantly ameliorated atherosclerosis by reducing the size of established plaques and the number of macrophages in the carotid arteries, aortic root, and whole aorta without causing lipid accumulation in the liver.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Induced PLTP deficiency in adult mice reduces plasma total cholesterol and triglycerides, prevents atherosclerosis progression, and promotes atherosclerosis regression. Thus, PLTP inhibition is a promising therapeutic approach for atherosclerosis.</p>

Targeting phosphatidylcholine-specific phospholipase C for atherogenesis therapy.

D609 Inhibits Progression of Preexisting Atheroma and Promotes Lesion Stability in Apolipoprotein E−/−Mice

Phospholipase C β3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice

Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice.

DVT: A New Era in Anticoagulant Therapy D609 Inhibits Progression of Preexisting Atheroma and Promotes Lesion Stability in Apolipoprotein E

Lipopolysaccharide activated phosphatidylcholine-specific phospholipase C and induced IL-8 and MCP-1 production in vascular endothelial cells.

Lipoprotein-associated Phospholipase A2:an Independent Predictor of Vascular Risk and a Novel Target for Therapy

Mammalian phosphatidylcholine-specific phospholipase Cs

Targeting annexin A7 by a small molecule suppressed the activity of phosphatidylcholine-specific phospholipase C in vascular endothelial cells and inhibited atherosclerosis in apolipoprotein E −/− mice

Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy

The Mechanisms of Lysophosphatidylcholine in the Development of Diseases

Phosphorylcholine-Primed Dendritic Cells Aggravate the Development of Atherosclerosis in ApoE-/- Mice.

Targeting Nanoplatform for Atherosclerosis Inhibition and Degradation via a Dual‐Track Reverse Cholesterol Transport Strategy

Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease

Programmed prodrug breaking the feedback regulation of P-selectin in plaque inflammation for atherosclerotic therapy

Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis

Protocatechuic aldehyde increases pericyte coverage and mitigates pericyte damage to enhance the atherosclerotic plaque stability

Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis

Targeted Delivery of Platelet Membrane Modified Extracellular Vesicles into Atherosclerotic Plaque to Regress Atherosclerosis

High expression of PLA2G2A in fibroblasts plays a crucial role in the early progression of carotid atherosclerosis

Dietary phosphatidylcholine supplementation reduces atherosclerosis in Ldlr-/- male mice2